Status:
NOT_YET_RECRUITING
Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients
Lead Sponsor:
Beijing Chao Yang Hospital
Collaborating Sponsors:
Beijing Municipal Health Commission
Conditions:
PAH
CTEPH
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise. PH...
Eligibility Criteria
Inclusion
- Confirmed PH Diagnosis:
- Right heart catheterization-confirmed pulmonary hypertension
- Meets 2022 ESC/ERS Guidelines diagnostic criteria for:
- Group 1 (PAH) or
- Group 4 (CTEPH/other pulmonary artery obstructions)
- Stabilized Treatment Status:
- Group 1 (PAH): Received ≥3 months of targeted drug therapy
- Group 4 (CTEPH): Completed ≥6 sessions of BPA\* or reached therapeutic endpoint
- Functional Capacity:
- WHO Functional Class I-III
- Age: ≥18 years
- Consent: Willing to provide written informed consent -
Exclusion
- Physical Limitations:
- Unable to perform pulmonary rehabilitation exercises due to disability or congenital malformations
- Cardiopulmonary Testing Contraindications:
- Medically unfit to complete CPET (cardiopulmonary exercise testing) after evaluation
- Poor Compliance:
- History of non-adherence making protocol completion unlikely
- Life Expectancy:
- Prognosis ≤1 year
- \-
Key Trial Info
Start Date :
May 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2027
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06973382
Start Date
May 20 2025
End Date
October 31 2027
Last Update
May 15 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.